Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 10Thoracic 5Breast 4Gynecologic 3Other solid neoplasm 2Other hematologic neoplasm 2Plasma cell 1Head & Neck 1Genitourinary 1

Conditions

Advanced Solid Tumors 2

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × MLN 8237 × Other solid neoplasm × Clear all
NCT00962091 2019-03-12

Study of MLN8237 in Participants With Advanced Solid Tumors

Takeda

Phase 1 Completed
53 enrolled 30 charts
Other solid neoplasm

Advanced Solid Tumors

NCT01094288 2019-02-15

A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

Takeda

Phase 1 Completed
41 enrolled 31 charts
GenitourinaryOther solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡